Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05770531 | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | recruiting | Phase 2 | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06118086 | Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | recruiting | Phase 1 / Phase 2 | 125 | Remix TherapeuticsINDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT06835972 |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) |
| recruiting |
| Phase 1 / Phase 2 |
| 43 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Jun 24, 2026 |
| clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04891068 | BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer(BRE-04) | recruiting | Phase 2 | 40 | University of Illinois at ChicagoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04947254 | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05726370 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | recruiting | Phase 2 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 91 | Syncromune, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06592599 | Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) | recruiting | Phase 2 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07158021 | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | recruiting | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | recruiting | Phase 2 | 25 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07387198 | Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab(NeoMatryx) | recruiting | Phase 2 | 135 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | recruiting | Phase 2 | 48 | Ronald BuckanovichOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07088211 | Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC | recruiting | Phase 2 | 39 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07090317 | Iparomlimab and Tuvonralimab in HNSCC | recruiting | Phase 2 | 30 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer(LOTS) | recruiting | Phase 1 / Phase 2 | 16 | Misty ShieldsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07339488 | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma(ILDR-03) | recruiting | Phase 2 | 43 | Chuangzhen ChenOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Peking University First HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07624487 | Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma | recruiting | Phase 2 | 50 | Taipei Medical University HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635238 | A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655622 | Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression(DUAL-THRUST) | recruiting | Phase 1 / Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04055649 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | recruiting | Phase 2 | 62 | Ira WinerOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04210492 | Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer | recruiting | Phase 1 / Phase 2 | 36 | Yale UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05570825 | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | recruiting | Phase 2 | 70 | Innate PharmaINDUSTRY | 5 | Jun 17, 2026 | clinicaltrials |
| NCT06925516 | A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC(ACADEMY) | recruiting | Phase 2 | 38 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07164170 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | recruiting | Phase 2 | 86 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06392295 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer(OCEAN) | recruiting | Phase 2 | 34 | University of MiamiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06479239 | Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer(Panc 002) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | recruiting | Phase 1 / Phase 2 | 30 | Huahui HealthINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07603856 | A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer(REVIVE) | recruiting | Phase 2 | 39 | University of ChicagoOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05589818 | Pembrolizumab for Advanced NSCLC and PS 2-3 | recruiting | Phase 2 | 45 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06364917 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | recruiting | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647289 | EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC | recruiting | Phase 2 | 58 | Peking University Third HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05239546 | Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers(NAIO) | recruiting | Phase 2 | 25 | University of IowaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2026source: clinicaltrials